Myanmar online crusaders hunt down shooter of brain-dead woman as Britain urgently considers sanctions

Online crusaders in Myanmar have begun to hunt for the officer who opened fire on a young female anti-coup protester, leaving her fighting for her life with a serious brain injury.

Mya Thwate Thwate Khaing should have been celebrating her 20th birthday on Thursday, but instead she has become a rallying cry for a pro-democracy movement that is gaining pace across the country in opposition to a military takeover on February 1.

Dominic Raab, the Foreign Secretary, announced on Thursday the United Kingdom is "urgently" looking at its own punitive measures against the junta that seized power last week, after the US imposed fresh sanctions.

Mr Raab said: "The international community will not accept the coup in Myanmar and we will hold those responsible to account.

"The UK welcomes [US president Joe Biden's] steps today to send a strong message to the military regime.

"[The UK] is urgently looking at further measures under our own sanctions regime."

Nicola Smith

Thu, February 11, 2021, 2:26 AM

Protesters gather outside the Chinese embassy in Myanmar - Nyein Chan Naing/EPA-EFE/Shutterstock

Protesters gather outside the Chinese embassy in Myanmar - Nyein Chan Naing/EPA-EFE/Shutterstock

Online crusaders in Myanmar have begun to hunt for the officer who opened fire on a young female anti-coup protester, leaving her fighting for her life with a serious brain injury.

Mya Thwate Thwate Khaing should have been celebrating her 20th birthday on Thursday, but instead she has become a rallying cry for a pro-democracy movement that is gaining pace across the country in opposition to a military takeover on February 1.

Dominic Raab, the Foreign Secretary, announced on Thursday the United Kingdom is "urgently" looking at its own punitive measures against the junta that seized power last week, after the US imposed fresh sanctions.

Mr Raab said: "The international community will not accept the coup in Myanmar and we will hold those responsible to account.

"The UK welcomes [US president Joe Biden's] steps today to send a strong message to the military regime.

"[The UK] is urgently looking at further measures under our own sanctions regime."

Doctors have told Mya Thwate Thwate Khaing's devastated family that she has little chance of survival. Amnesty International says it has verified footage of the incident and says "police recklessly targeted protesters” with live ammunition.

Images from the incident show a member of the police wielding a Myanmar-made variant of the Uzi sub-machine gun.

The accusations contradict Myanmar military claims that security forces were not carrying lethal weapons. The identity of the gunman remains unknown but Facebook and Twitter users have launched an online hunt.

Some have posted private details - including the home address and family business locations - of a man they suspect fired the bullet.

The target has denied the allegations and proclaimed his innocence in a Facebook post.

"On Facebook today, I am very sorry to see that my pictures (taken from my Facebook) are being compared to the picture of the police officer from the Naypyidaw shooting today," the man wrote in response.

"This misrepresentation has caused a great deal of damage."

Protests against the coup in Myanmar continued on Thursday, with thousands of people demonstrating outside China’s embassy in Yangon over allegations Beijing is supporting the junta and rumours that Chinese internet specialists had been flown in to help implement a controversial new cyber security law.

After orchestrating a coup and arresting the country’s civilian leaders on February 1, the military leadership is now pushing forward with a bill that would give it sweeping powers to ban content it dislikes, restrict internet providers and intercept data.

The Chinese embassy did not give an immediate response to the rally outside its gates but late on Wednesday, it used Facebook to post a denial of internet rumours that planes that arrived this week from China brought in technical personnel. It said the cargo flights were carrying seafood.

When asked about the reports, Chinese foreign ministry spokesman Wang Wenbin said there had been “false information and rumours” circulating about China on issues relating to Myanmar.

Beijing has denied it is backing the military junta, but its response to the generals’ sudden seizure of power has been muted, with China calling itself a “friendly neighbour” and urging all sides to “handle their differences.”

The UN Security Council last week called for the release of elected leader Aung San Suu Kyi and others detained by the military but stopped short of condemning the coup after objections from China and Russia.

more

https://www.yahoo.com/news/myanmar-online-crusaders-hunt-down-102610335.html

>>12891794

If you add the "T" from "THE" you get TARP.

Blanket of Evil.

>>12891836

>The choice to know will be yours

That line is confusing.

Does it mean, that the only ones who will KNOW, are the ones who dig and find info, that others say is fake? So, basically, like now? Always labeled the crazy ones by the deceivers?

>>12892008

>>12892006

Been taking Chlorella for years.

Chlorella is a fantastic supplement to add to your heavy metal detox protocol.

Why? Because, in addition to its ability to bind to heavy metals, chlorella also contains a lot of important vitamins and minerals that could help your body during the detox process.

https://beautyandwellbeing.com/well-being/chlorella-heavy-metal-detox/

>>12892139

Notable

Roche's tocilizumab cuts deaths in hospitalised COVID-19 patients - study

LONDON, Feb 11 (Reuters) - Roche's arthritis drugtocilizumab cuts the risk of death among patients hospitalisedwith severe COVID-19, also shortening the time to recovery andreducing the need for mechanical ventilation, results of a largetrial showed on Thursday.

The findings - from the RECOVERY trial, which has beentesting a range of potential treatments for COVID-19 since March2020 - should help clear up confusion about whether tocilizumabhas any benefit for COVID-19 patients after a slew of recentmixed trial results.

"We now know that the benefits of tocilizumab extend to allCOVID patients with low oxygen levels and significantinflammation," said Peter Horby, a professor of emerginginfectious diseases at Oxford University and the joint leadinvestigator on the RECOVERY trial.

In June last year, the RECOVERY trial found that the cheapand widely available steroid dexamethasone reduced death ratesby around a third among the most severely ill COVID-19 patients.That drug has since rapidly became part of standard-of-carerecommended for severe patients.

Tocilizumab, sold under the brand name Actemra, is anintravenous anti-inflammatory monoclonal antibody drug used totreat rheumatoid arthritis. It was added to the trial in April2020 for patients with COVID-19 who required oxygen and hadevidence of inflammation.

The study data were from 2,022 COVID-19 patients who wererandomly allocated to receive tocilizumab by intravenousinfusion and who were compared with 2,094 patients randomlyallocated to usual care alone. Researchers said 82% of allpatients were taking a systemic steroid such as dexamethasone.

Results showed that treatment with tocilizumab significantlyreduced deaths - with 596 (29%) of the patients in thetocilizumab group dying within 28 days, compared with 694 (33%)patients in the usual care group.

This translates to an absolute difference of 4% and meansthat for every 25 patients treated with tocilizumab, oneadditional life would be saved, Horby and his co-leadinvestigator Martin Landray said.

They added that benefits of tocilizumab were clearly seen tobe in addition to those of steroids.

"Used in combination, the impact is substantial," saidLandray, who is also an Oxford professor of medicine andepidemiology.

He added that results "clearly show the benefits oftocilizumab and dexamethasone in tackling the worst consequencesof COVID-19 – improving survival, shortening hospital stay, andreducing the need for mechanical ventilators."

Roche's drug division chief Bill Anderson said lastweek that previous mixed results were likely due to differencesin the type of patients studied, when they were treated, and theendpoint - the juncture at which success or failure is measured.

"We think we're sort of zooming in on both the most relevantendpoints and relevant patient population," Anderson said. "Itseems like the ideal candidates are patients who are really inthat acute phase of inflammatory attack."

Actemra, along with Sanofi's similar drug Kevzara,was authorized by Britain's NHS in early January for COVID-19patients in intensive care units after preliminary data from asmaller study called REMAP-CAP indicated it could reducehospital stays by about 10 days.

During 2020, Actemra rose to become Roche'sfifth-best-selling drug, at more than $3 billion, with nearly$600 million from COVID-19 treatment.(Reporting by Kate Kelland in LONDON, with additional reportingby John Miller in ZURICH. Editing by David Evans)

https://www.yahoo.com/finance/news/roches-tocilizumab-cuts-deaths-hospitalised-150000883.html